Today: 11 June 2026
Marathon Petroleum stock jumps nearly 6% premarket as Venezuela oil bets lift U.S. refiners
5 January 2026
1 min read

Marathon Petroleum stock jumps nearly 6% premarket as Venezuela oil bets lift U.S. refiners

NEW YORK, Jan 5, 2026, 05:42 ET — Premarket

  • Marathon Petroleum shares rose about 5.8% in premarket trading, tracking a broader jump in U.S. refining stocks tied to Venezuela headlines.
  • Traders are weighing whether easier access to Venezuelan heavy crude could benefit Gulf Coast refiners’ feedstock slate.
  • Focus turns to U.S. policy signals on Venezuelan crude exports, plus key U.S. data this week and MPC’s next earnings window.

Marathon Petroleum Corporation shares jumped 5.75% to $174.63 before the opening bell on Monday, extending energy-sector momentum sparked by Washington’s latest moves in Venezuela.

The rally comes as investors bet the U.S. crackdown on Venezuela’s leadership could loosen restrictions around Venezuelan crude and shift more barrels toward American buyers. That matters for refiners because crude type and location can move costs — and margins — quickly when supplies are tight or discounted.

Venezuelan crude is typically “heavy sour” — oil with higher sulfur content — and U.S. Gulf Coast plants were built decades ago to run heavier grades. Ahmad Assiri, research strategist at Pepperstone, said that crude “aligns well with the configuration of U.S. Gulf Coast refineries.” Reuters

The move in MPC mirrored gains across the group. Reuters reported Chevron was up 7.3% in premarket trading, while refiners including Phillips 66, Valero Energy and PBF Energy were also higher.

Oil prices, however, slipped even as the geopolitical stakes rose. Brent crude fell 0.4% to $60.54 a barrel and U.S. WTI dropped 0.5% to $57.04, with traders pointing to ample supply and OPEC+ holding output steady.

A Reuters Breakingviews column said the bigger near-term story for refiners could be trade flows rather than new production. If more Venezuelan exports are redirected toward the United States, U.S. refiners could see an “immediate boost,” even if a sustained recovery in Venezuelan output takes longer. Reuters

For Marathon, the key watch is refining margin — the spread between what it pays for crude and what it sells fuels for. Traders often track that through crack spreads, a shorthand for the gap between prices of products like gasoline and diesel and the cost of crude.

The stock’s premarket jump pushed it closer to the upper end of its recent range. MPC has traded between $115.10 and $202.30 over the past 52 weeks, based on market data, and early trading showed a narrow premarket band around $174.50–$174.64.

There is a catch: analysts have warned that any meaningful recovery in Venezuelan oil production would take time given political uncertainty, infrastructure decay and years of underinvestment. Venezuelan heavy sour crude can also carry lower margins than some competing grades, which could cap the benefit if product prices do not keep pace.

Stock Market Today

  • Wall Street Gains on AI Stock Rally Amid Inflation and Middle East Tensions
    June 11, 2026, 11:16 AM EDT. Wall Street recovered some weekly losses Thursday as artificial intelligence (AI) stocks rebounded, led by chipmakers like Marvell Technology (+5.5%), Intel (+7.8%), and Applied Materials (+7.5%). The S&P 500 rose 0.5%, Dow Jones 0.7%, and Nasdaq 0.7%. Despite market gains, concerns about elevated AI valuations persist, while Oracle shares fell 11.1% after revealing plans to raise $40 billion to fund AI investments. Oil prices remained steady despite rising tensions in the Iran conflict, with Brent crude at $92.64 and U.S. crude at $90.29 per barrel. Meanwhile, wholesale inflation in the U.S. exceeded expectations in May, prompting the European Central Bank to raise interest rates, signaling global inflationary pressures.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
BAE Systems shares jump nearly 5% as Venezuela shock lifts European defense stocks
Previous Story

BAE Systems shares jump nearly 5% as Venezuela shock lifts European defense stocks

NuScale Power stock jumps 16% as House sets ‘New Nuclear Era’ hearing — what’s next for SMR
Next Story

NuScale Power stock jumps 16% as House sets ‘New Nuclear Era’ hearing — what’s next for SMR

Go toTop